KDIGO clinical practice guidelines for bisphosphonate treatment in chronic kidney disease

Kidney International

Volumn 80, Issue 5, 2011, Pages 553-554

  Woo, Keng T ^a   Chan, Choong M ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CREATININE; NONSTEROID ANTIINFLAMMATORY AGENT; BONE DENSITY CONSERVATION AGENT;

CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EXCRETION; FRACTURE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; LETTER; MEDICAL ASSESSMENT; MORBIDITY; MORTALITY; PERITONEAL DIALYSIS; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; METABOLIC BONE DISEASE; NOTE;

BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; DIPHOSPHONATES; FRACTURES, BONE; HUMANS; KIDNEY DISEASES;

EID: 84857084186     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.202     Document Type: Letter

References (7)

1. Przedlacki J. Comments on KDIGO clinical practice guidelines for bisphosphonate treatment of chronic kidney disease. Kidney Int 2010; 78: 1186.
2. Kidney Disease-Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009; 76: S1-S130.
3. Marron B, Remon C, Perez-Fontan M et al. Benefits of preserving residual renal function in PD. Kidney Int 2008; 73: S42-S51. (Pubitemid 351466516)
4. Health Science Authority, Singapore Adverse Drug Reaction News. August 2010, vol 12, No. 2, p 2.
5. FDA Drug Safety Newsletter, vol 2, No. 2, 2009. Zoledronic acid (marketed as Reclast): Renal impairment and acute renal failure. http://www.fda.gov/ Drugs/DrugSafety/DrugSafetyNewsletter/ucm167883.htm.
6. MHRA Drug Safety Update: vol 3. Issue 9, April 2010. Intravenous zoledronic acid: adverse effects on renal function. http://www.mhra.gov.uk/ Publications/Safetyguidance/DrugSafetyUpdate/CON076501.
7. HSA website Dear Healthcare Professional Letters (DHCPL). http://www.hsa.gov.sg/DHCPL.